Clinical Trials List
2022-02-01 - 2025-07-31
Phase I
Terminated1
ICD-10C7A.1
Malignant poorly differentiated neuroendocrine tumors
ICD-10C7A.8
Other malignant neuroendocrine tumors
ICD-10C7B.09
Secondary carcinoid tumors of other sites
ICD-10C7B.1
Secondary Merkel cell carcinoma
ICD-10C7B.8
Other secondary neuroendocrine tumors
ICD-10C80.0
Disseminated malignant neoplasm, unspecified
ICD-10D3A.8
Other benign neuroendocrine tumors
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9199.0
Disseminated malignant neoplasm
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/03/01
Investigators and Locations
Co-Principal Investigator
- 徐偉勛 Division of Hematology & Oncology
- Wei-Wu Chen Division of Hematology & Oncology
- Jih-Hsiang Lee Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
40 participants
-
Global
320 participants
